What could cause a phantom smell of smoke when lisdexamfetamine (Vyvanse) wears off, and how should it be managed?

Phantom Smoke Smells During Vyvanse Wear-Off

This symptom likely represents a withdrawal-related phenomenon or "rebound" effect as lisdexamfetamine's therapeutic effects diminish, though it could also signal a psychiatric adverse reaction requiring immediate evaluation.

Understanding the Mechanism

Lisdexamfetamine (Vyvanse) is a prodrug that converts to d-amphetamine, which increases dopamine and norepinephrine release in the brain 1. When the medication wears off, there can be an abrupt shift in neurotransmitter availability, potentially triggering perceptual disturbances including phantom odors (phantosmia).

The FDA label explicitly warns that withdrawal symptoms after dose reduction or discontinuation can include "vivid, unpleasant dreams" and other perceptual changes 1. While phantom odors aren't specifically listed, they fall within the spectrum of withdrawal-related sensory phenomena.

Critical Differential: Rule Out Psychosis First

You must immediately assess whether this represents a stimulant-induced psychotic reaction, which is a serious adverse event. The FDA label warns that Vyvanse can cause "hallucinations" and "psychotic symptoms" even at recommended doses 1.

Red flags requiring immediate discontinuation:

• Phantom smells accompanied by paranoia, agitation, or confusion
• Visual or auditory hallucinations
• Disorganized thinking or behavior
• Symptoms occurring during peak medication effect (not just wear-off)

If any psychotic features are present, stop Vyvanse immediately and evaluate for alternative ADHD treatments 2.

If This is Rebound/Withdrawal Phenomenon

Assuming psychosis is ruled out, this appears to be a "rebound" effect. Guidelines specifically address managing rebound symptoms 2:

Management strategies in order of preference:

1. Overlap dosing pattern: Add a small afternoon dose to smooth the transition as the morning dose wears off
2. Switch to longer-acting formulation: Though Vyvanse is already long-acting, some patients benefit from combining it with a small immediate-release dose in late afternoon
3. Add adjunctive medication: Consider adding a non-stimulant like guanfacine or clonidine for evening coverage
4. Reduce the dose: Paradoxically, sometimes lowering the dose reduces rebound intensity 2

The Olfactory Connection

Research shows that polypharmacy (≥5 medications) increases phantom odor risk by 70% 3, and stimulants specifically alter olfactory processing. One study demonstrated that lisdexamfetamine changes brain activation patterns in olfactory centers and inhibitory regions 4. Interestingly, untreated ADHD patients show heightened odor sensitivity, which normalizes with stimulant treatment 5.

This suggests your patient may be experiencing a rebound to their baseline heightened olfactory sensitivity as medication wears off, potentially manifesting as phantom perceptions.

Practical Management Algorithm

Step 1: Screen for psychotic symptoms (paranoia, disorganization, other hallucinations)

• If present → discontinue Vyvanse immediately

Step 2: If no psychosis, assess timing

• Occurs only during wear-off (evening) → rebound phenomenon
• Occurs throughout day → consider alternative causes

Step 3: For confirmed rebound:

• First try: Add 20-30mg immediate-release amphetamine at 3-4pm
• If ineffective: Consider switching to methylphenidate-based stimulant (different pharmacology may help)
• If persistent: Add evening clonidine 0.1mg for symptom coverage

Step 4: If symptoms persist despite adjustments, consider non-stimulant alternatives (atomoxetine, viloxazine)

Important Caveats

• Document carefully: Phantom smells can be early warning signs of more serious psychiatric adverse reactions
• Monitor for progression: If symptoms worsen or occur during peak medication effect, this changes the clinical picture significantly
• Consider neurological evaluation if symptoms persist off medication, as phantosmia can indicate other pathology (though less likely given temporal relationship to medication)
• Avoid dismissing the symptom: While uncommon, it's causing distress and warrants intervention

The key distinction is whether this represents dangerous stimulant-induced psychosis versus manageable rebound effects. The temporal relationship (occurring specifically during wear-off) and absence of other psychotic features would favor the latter, making dose adjustment or timing modification the appropriate first step 2.